✦ LIBER ✦

The challenges of conducting clinical endpoint studies

✍ Scribed by Jonathan L. Isaacsohn; Tiffany A. Khodadad; Catherine Soldano-Noble; Jeffrey D. Vest

Book ID: 107533760
Publisher: Current Science Inc.
Year: 2003
Tongue: English
Weight: 166 KB
Volume: 5
Category: Article
ISSN: 1523-3804
DOI: 10.1007/s11883-003-0062-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Validation of quantitative endpoints for

Validation of quantitative endpoints for clinical trials: An emerging challenge

✍ Hervé P. Lefebvre; Didier Concordet 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 105 KB

Conducting Effectiveness Studies in the

Conducting Effectiveness Studies in the Context of Evidence-Based Clinical Practice

✍ Jacqueline B. Persons 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

Recommendations for conducting controlle

Recommendations for conducting controlled clinical studies of dental restorative materials

✍ R. Hickel; J.-F. Roulet; S. Bayne; S. D. Heintze; I. A. Mjör; M. Peters; V. Rous 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 542 KB

Recommendations for conducting controlle

Recommendations for conducting controlled clinical studies of dental restorative materials

✍ R. Hickel; J.-F. Roulet; S. Bayne; S. D. Heintze; I. A. Mjör; M. Peters; V. Rous 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 39 KB

A retrospective study of the time to cli

A retrospective study of the time to clinical endpoints for advanced prostate cancer

✍ Nima Sharifi; William L. Dahut; Seth M. Steinberg; William D. Figg; Christopher 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

American association for the study of li

American association for the study of liver diseases endpoints conference: Design and endpoints for clinical trials in primary biliary cirrhosis

✍ Marina G. Silveira; Elizabeth M. Brunt; Jenny Heathcote; Gregory J. Gores; Keith 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB 👁 1 views

A group of multidisciplinary experts on primary biliary cirrhosis (PBC) and its complications convened on May 31, 2009, under the aegis of the American Association for the Study of Liver Diseases (AASLD) in order to identify the most appropriate design and endpoints for clinical trials of PBC based